Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00749632 · ClinicalTrials.gov registry record · Phase 2
A Study of Oxybutynin for the Treatment of Urge Urinary Incontinence
A Phase 2 study of Urinary Incontinence, Urge, sponsored by FemmePharma Global Healthcare.
- Completed
- Registry status
- Phase 2
- Development phase
- 45
- Enrollment target
- 2
- Study locations
NCT00749632: Completed Phase 2 study of Urinary Incontinence, Urge, sponsored by FemmePharma Global Healthcare.
NCT00749632 is a Phase 2 study of Urinary Incontinence, Urge that has completed, run by FemmePharma Global Healthcare. The registered enrollment target is 45 participants, below the 153-participant average among 9 other Urinary Incontinence, Urge trials with a reported enrollment target (71% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00749632, a Phase 2 study of Urinary Incontinence, Urge, has completed, sponsored by FemmePharma Global Healthcare.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 45 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to determine the safety of three doses of oxybutynin for the treatment of urge urinary incontinence.
Conditions Studied
Interventions
- DRUG oxybutynin
Study Locations (2)
Maryland
- SNBL Clinical Pharmacology Center - Baltimore
New Jersey
- Advanced Biomedical Research - Hackensack
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2007-07 |
| Est. Completion | 2008-10 |
| Phase | Phase 2 |
What the finished NCT00749632 record still lists
NCT00749632 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 45 participants, a relatively small participant target, below the 153-participant average among 9 other Urinary Incontinence, Urge trials with a reported enrollment target (71% lower).
The record links to 1 condition, with Urinary Incontinence, Urge appearing as the primary indexed condition, and to 1 intervention - of which oxybutynin is the first listed.
NCT00749632 reports a single indexed study location in Maryland, New Jersey.
Frequently Asked Questions
What is clinical trial NCT00749632 about?
NCT00749632 is a clinical study titled "A Study of Oxybutynin for the Treatment of Urge Urinary Incontinence". The purpose of this study is to determine the safety of three doses of oxybutynin for the treatment of urge urinary incontinence.
What is the current status of trial NCT00749632?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 45 participants. The study started on 2007-07. Estimated completion is 2008-10.
What conditions does trial NCT00749632 study?
This clinical trial studies the following conditions: Urinary Incontinence, Urge.
What interventions are being tested in trial NCT00749632?
The interventions under investigation include: oxybutynin (DRUG).
Who is sponsoring clinical trial NCT00749632?
This trial is sponsored by FemmePharma Global Healthcare, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00749632 being conducted?
This trial has 2 study locations across Maryland, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Urinary Incontinence, Urge
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00749632's enrollment target sits among peer trials
45 8th of 9 higher than 2 of 9 other Urinary Incontinence, Urge trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Urinary Incontinence, Urge trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
NXT Post-Market Clinical Follow-up
RECRUITING
-
TReating Incontinence for Underlying Mental and Physical Health
RECRUITING · Phase 4
-
rTMS in Overactive Bladder
RECRUITING · NA
-
Mobility and Voiding Exercises in Older Women With Urinary Incontinence (MoVEonUp)
ACTIVE NOT RECRUITING · NA
-
INTIBIA Pivotal Study
ACTIVE NOT RECRUITING · NA
-
Efficacy of Animated Videos to Foster Healthy Bladder Behaviors in Community Women
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00804154 · 45 participants · Phase 1
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
- NCT01851694 · 45 participants · NA
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
- NCT02896335 · 45 participants · Phase 2
Palbociclib and Pembrolizumab In Central Nervous System Metastases
- NCT03454035 · 45 participants · Phase 1
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia